Human plasma protein levels alter the in vitro antifungal activity of caspofungin: An explanation to the effect in critically ill?

Siri Kurland1 | Elisabeth Löwdin1 | Mia Furebring1 | Ayda Shams1 | Erja Chryssanthou2 | Pernilla Lagerbäck1 | Thomas Tängden1 | Olof Breuer3 | Jan Sjölin1

1Department of Medical Sciences, Uppsala University, Uppsala, Sweden
2Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden
3Department of Laboratory Medicine, Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

Correspondence
Siri Kurland, Department of Medical Sciences, Uppsala University Hospital, 751 85 Uppsala, Sweden.
Email: siri.kurland@medsci.uu.se

Funding information
This work was funded by the Olinder-Nielsen Family Fund for Research in Infectious Diseases and R&D funds of the Uppsala County Council. Thomas Tängdén acknowledges financial support from the Swedish Research Council (grant nos. 2019-05911 and 2020-02320)

Abstract

Background: Recent studies have shown low caspofungin concentrations in critically ill patients. In some patients, the therapeutic target, area under the total plasma concentration curve in relation to the minimal inhibition concentration (AUCtot/MIC), seems not to be achieved and therapeutic drug monitoring (TDM) has been proposed. Caspofungin is highly protein-bound and the effect of reduced plasma protein levels on pharmacodynamics has not been investigated.

Objectives: Fungal killing activity of caspofungin in vitro was investigated under varying levels of human plasma protein.

Methods: Time-kill studies were performed with clinically relevant caspofungin concentrations of 1-9 mg/L on four blood isolates of C. glabrata, three susceptible and one strain with reduced susceptibility, in human plasma and plasma diluted to 50% and 25% using Ringer's acetate.

Results: Enhanced fungal killing of the three susceptible strains was observed in plasma with lower protein content (p < .001). AUCtot/MIC required for a 1 log10 CFU/ml kill at 24 h in 50% and 25% plasma was reduced with 36 ± 12 and 80 ± 9%, respectively. The maximum effect was seen at total caspofungin concentrations of 4–9 × MIC. For the strain with reduced susceptibility, growth was significantly decreased at lower protein levels.

Conclusions: Reduced human plasma protein levels increase the antifungal activity of caspofungin in vitro, most likely by increasing the free concentration. Low plasma protein levels in critically ill patients with candidemia might explain a better response to caspofungin than expected from generally accepted target attainment and should be taken into consideration when assessing TDM based on total plasma concentrations.

KEYWORDS
antifungal activity, caspofungin, free concentration, plasma protein, protein-binding
1 | INTRODUCTION

Candidemia, the most common form of invasive candidiasis, has a major impact on morbidity and mortality in intensive care unit (ICU) patients. Caspofungin, an antifungal agent with a high protein binding of approximately 97%, is currently together with other echinocandins recommended as first-line therapy in invasive candidiasis. However, the critically ill have altered pathophysiological processes that may influence antifungal pharmacokinetics (PK), including changes in drug-protein binding. Albumin is the major drug-binding protein, and hypoalbuminemia is common in this patient group due to protein losses via capillary leakage, decreased production and dilution by fluid resuscitation.

Recent pharmacokinetic/pharmacodynamic (PK/PD) analyses have indicated that caspofungin has a relatively high degree of target attainment expressed as area under the free concentration curve divided by the MIC (AUC_free/MIC) for a net stasis effect. However, clinical studies on intensive care patients at considerable risk for candidemia indicate lower AUCs calculated from total plasma concentrations (AUC_tot) than those employed in the PK/PD analysis above. Furthermore, these studies found that concentrations necessary to reach a killing effect were not always achieved.

Total concentration is the sum of free and protein-bound concentrations by which only the unbound free fraction of the drug is generally considered pharmacologically active. Therefore, one explanation to the favourable outcome in the clinical studies could be a higher free drug concentration than deduced from the total concentration due to a reduction in the number of binding sites in hypoalbuminemia. The importance of free concentration for the antimicrobial effect has been well demonstrated for antibiotics, whereas studies with antifungals are limited. There are in fact data questioning the importance of free antifungal drug concentrations. An analysis of pooled data from six prospective clinical studies found echinocandin treatment effective in candidemia caused by Candida parapsilosis despite MIC values well above calculated free drug concentrations. Similarly, it has been experimentally shown that the highly protein-bound antifungal posaconazole exerts its effect on different Candida spp. at calculated free concentrations lower than the MIC values, suggesting a rapid and direct flux of the drug from plasma proteins to the fungal target.

For these reasons, analysis of the free concentration of caspofungin at different levels of albumin and other plasma proteins is of interest. At present, such an analysis is hampered by technical difficulties and commercial methods are not available. The present study aimed to investigate the influence of plasma protein levels on the PD activity of caspofungin in human plasma to explore the impact of free antifungal concentration. Time-kill experiments were performed using four clinical blood isolates of Candida spp. due to their inability to develop pseudohyphae, thereby increasing the precision of the viable count. Four clinical blood isolates, three susceptible strains and one with reduced susceptibility, were obtained from the Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden. Antifungal susceptibility testing was performed using Sensitive Yeast One® (Thermo Fisher Diagnostics AB). MIC values for the isolates were 0.06 (ARU459), 0.12 (ARU455), 0.12 (ARU767) and 1 mg/L (ARU792).

2 | MATERIAL AND METHODS

2.1 | Strains and antifungal susceptibility testing

Candida glabrata strains were used as representatives for the Candida spp. due to their inability to develop pseudohyphae, thereby increasing the precision of the viable count. Four clinical blood isolates, three susceptible strains and one with reduced susceptibility, were obtained from the Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden. Antifungal susceptibility testing was performed using Sensitive Yeast One® (Thermo Fisher Diagnostics AB). MIC values for the isolates were 0.06 (ARU459), 0.12 (ARU455), 0.12 (ARU767) and 1 mg/L (ARU792).

2.2 | Antifungal agent

Stock solutions of caspofungin (Sigma-Aldrich AB) were prepared in sterile water according to the manufacturer’s instructions and diluted to the desired concentration in phosphate-buffered saline (PBS) immediately before use.

2.3 | Plasma

Plasma from three blood donors was frozen without any previous treatment and used for all the time-kill experiment. Prior to the start of each experiment, plasma was thawed and carefully warmed to 36 ± 1°C.

2.4 | Time-kill experiments

2.4.1 | Effects of plasma protein levels

Initially, the isolates were cultured on Sabouraud dextrose agar (SDA) plates in 36 ± 1°C for 48 h. Three colonies were transferred to 7.5 ml yeast extract peptone dextrose (YPD) medium and incubated with agitation overnight at 36 ± 1°C. An aliquot of 200 µl from the YPD-containing tube was serially diluted in PBS and transferred to the plasma-containing time-kill tubes resulting in a starting inoculum of 2–7 × 10^4 CFU/ml. Caspofungin was added to clinically relevant total concentrations of 1.0, 2.0, 5.0 and 9.0 mg/L resulting in a final volume of 2 ml. Identical set-ups were performed in plasma diluted using a Ringer’s Acetate solution (RI-Ac) to 50% and 25%. The time-kill tubes were placed on a shaker and incubated at 36 ± 1°C. Aliquots of 250 µl were sampled at 0, 2, 6 and 24 h, serially diluted in PBS and 100 µl inoculated onto SDA plates for viable counts. The plates were incubated at 36 ± 1°C for 24 h. The lower limit of detection was 10 CFU/ml. All experiments were performed in triplicate and on separate days. Antifungal carryover effects were assessed by placing the aliquots as a drop on the SDA plates, allowed to soak into the agar, after which the sample was spread. If colony count was reduced adjacent
to where the aliquot was placed, the plate was divided into sections and the section with reduced colony count was excluded.

In separate experiments with identical set-ups as above, caspofungin concentrations of 0.06, 0.12, 0.25 and 0.50 mg/L were used to define the concentration resulting in a net static effect, that is neither killing nor growth had occurred at 24 h in relation to the starting inoculum. These concentrations are referred to as subclinical concentrations.

2.4.2 | Effect of changes in pH

The effect of pH on PD was explored to detect potential effects caused by Ri-Ac and carbon dioxide release from the plasma in vitro, as well as possible pH changes in critically ill patients. In screening experiments, the pH range was established by measurements in each medium planned for the time-kill experiments, that is 100%, 50% and 25% plasma, with and without caspofungin. To assess the impact of pH on caspofungin PD, time-kill experiments with caspofungin were performed, as described above, with concentrations of 0.5 and 1.0 mg/L expected to give free concentrations close to the MICs of the susceptible strains. The initial pH was set to 6.80, 7.15, 7.40 and 7.70, with experiments executed in 100% and 25% plasma. Hydrochloric acid or sodium bicarbonate was added as needed to achieve the desired pH.

2.5 | Statistics and calculations

Colony counts displayed in text and figures are expressed as mean \( \log_{10} \text{CFU/ml} \pm \text{standard deviation (±SD)} \) unless otherwise indicated. \( \log_{10} \) values of samples with a viable count <10 CFU/ml were set to 0.5. The 24-h AUC based on total concentrations required for 1 \( \log_{10} \) CFU/ml kill at 24-h (AUC \(_{tot}\)) for the susceptible strains was calculated by identifying two caspofungin concentrations: the highest concentration that did not attain 1 \( \log_{10} \) CFU/ml kill compared to the starting inoculum and the lowest caspofungin concentration that resulted in more than 1 \( \log_{10} \) CFU/ml kill. Utilising the results from these two concentrations, the caspofungin concentration resulting in a 1 \( \log_{10} \) CFU/ml kill was derived by linear extrapolation. From this concentration, the 24-h AUC then was computed by multiplying the concentration by 24.

Mixed models with the unstructured covariance structure for the repeated effect were used to statistically analyse differences in growth. Mixed models were preferred to repeated measure ANOVA since Mauchly’s test of sphericity demonstrated that at least one of the assumptions for the compound symmetry covariance structure was violated. Differences in viable count at the end of the experiment at 24 h for the various caspofungin concentrations were additionally analysed using the independent t test, two-tailed. Statistical significance was defined as a p-value of <.05. SPSS software (version 24; IBM® Armonk) was employed to analyse the data.

2.6 | Ethics statement

The authors confirm that the ethical policies of the journal, as noted on the journal’s author guidelines page, have been adhered to. No ethical approval was required as the research in this article related to microorganisms.

3 | RESULTS

3.1 | Time-kill experiments

3.1.1 | The effect of pH

The screening experiments showed a difference in pH at 0 h with values of 7.60 ± 0.01, 7.54 ± 0.03 and 7.09 ± 0.09 in 100%, 50% and 25% plasma, respectively. Addition of varying amounts of caspofungin did not affect the pH. Fungal growth of the four strains was not affected by manipulating the pH at 0 h. Growth after 24 h exposure to caspofungin at the lowest clinical concentration of 1 mg/L in 100% and 25% plasma showed no significant differences in viable count (Figure 1). Similar results were observed at 2 and 6 h and at all time points with caspofungin in the subclinical concentration of 0.5 mg/L. Detailed information on the effect of pH is presented in the Supplementary data (Supplementary information and Figures...
S1A–C). The effect of pH was minimal; therefore, it was left unadjusted in the pivotal time-kill experiments.

3.1.2 | The effect of plasma protein levels

The results of lowering the plasma fraction from 100% to 50% and 25% in time-kill experiments with ARU455, 459 and 767 are displayed in Figure 2. The growth of the three strains in caspofungin-free controls did not differ based on the plasma protein content. The enhanced fungal killing in media with lower plasma fractions increased over the 24-h period of the experiments and differences in killing were highly significant when the three strains were analysed together (p < .001). When analysed separately, the effect was also significant (p < .05) for the strains ARU455 and ARU767. ARU459 exhibited a similar trend, albeit non-significant. The effect of decreasing the plasma protein content was more evident at the lower clinical caspofungin concentrations of 1 and 2 mg/L than at higher concentrations. To reduce inter-strain variation, the results for ARU792 with reduced susceptibility are shown separately in Figure 3. There was no fungal killing but, similarly to ARU455 and ARU767, growth was significantly reduced at the lower protein levels (p < .05).

Time-kill curves for ARU455, 459 and 767 after exposure to sub-clinical caspofungin concentrations are depicted in Figure 4. There was an increased killing in all strains when plasma was diluted also at these concentrations. At concentrations, at which a net static effect occurred, inhibition of growth was similarly affected (Table 1).

Total caspofungin concentration achieving a $1 \log_{10}$ CFU/ml reduction from the starting inoculum at 24 h in the different protein-containing media and the effect on $AUC_{tot}/MIC$ in the fully susceptible strains are listed in Table 2. The $AUC_{tot}/MIC$ in 50% was reduced with 36 ± 12 and in 25% plasma with 80 ± 9%. For the strain with reduced susceptibility, ARU792, $1 \log_{10}$ CFU/ml kill at 24 h was not achieved even at the highest concentration of 9 mg/L. Although $>1 \log_{10}$ CFU/ml lower than the control, there was an increase of 0.2 $\log_{10}$ CFU/ml at this concentration in 100% plasma (Figure 3). This
The magnitude of response was seen at a concentration of 5 mg/L in 50% plasma and of 1–2 mg/L in 25% plasma, suggesting a similar plasma protein-dependent effect also in this strain.

**4 | DISCUSSION**

Our results indicate that caspofungin has an increased fungal killing activity in terms of a lower $AUC_{\text{tot}} / \text{MIC}$ to attain a 1 log$_{10}$ CFU/ml kill at 24 h in the presence of lower plasma protein concentrations. This effect is most likely caused by a higher fraction of free unbound caspofungin as the total concentration of caspofungin is the same. In vivo unbound caspofungin is more available for elimination, probably explaining the association with low AUCs and low plasma albumin levels seen in previous studies. However, our data indicate that fungal killing is increased in relation to what can be expected from the low $AUC_{\text{tot}}$ at low plasma protein levels.

Critically ill patients treated with caspofungin have maximal total plasma concentrations ($C_{\text{max}}$) in the range of 1–9 mg/L and trough concentrations in the range of 0.5–2.5 mg/L. The effect of reducing protein levels is most pronounced at low caspofungin concentrations, (Figures 2 and 4). If the differences in growth between 100% and 25% plasma at different caspofungin concentrations for the four strains are depicted, a gradual relationship emerges (Figure 5). The enhanced activity for the susceptible strains is limited at the lowest and the highest concentrations, 0.06 and 9 mg/L, respectively. This is likely due to limited or no antifungal activity at the lowest concentration and a near-maximal activity already achieved in undiluted plasma at the highest concentration. There is an increase in antifungal enhancement in the 25% plasma up to a maximal effect at concentrations of $4–9 \times \text{MIC}$ after which there is a gradual fall. There is a similar MIC-dependent manifestation in the strain with reduced susceptibility, but concentrations above $10 \times \text{MIC}$ for this particular strain are not clinically relevant and therefore not tested. Our results support the discussion by Zeitlinger et al. that the most pronounced PD effect of protein binding occurs at concentrations relatively close to the MIC.

Plasma protein levels are mirrored by the albumin concentration, the major drug transporter with concentrations in healthy individuals.
In the general ICU population with suspected severe sepsis, albumin levels are decreased to values often lower than 30 g/L and even more so in patients with suspected fungal infection. Muilwijk et al. found that more than 80% had albumin values of <24 g/L. In a similar study by our group most patients had values below 20 g/L, some close to 10 g/L, that is albumin levels corresponding to a plasma protein reduction of approximately 75%, the magnitude of the lowest plasma protein content used in the current study.

The PD 24-h target can be expressed as either a net stasis or a 1 log₁₀ CFU/ml kill effect. In the present study, a 1 log₁₀ CFU/ml kill was chosen based on the assumption that the superior effect of echinocandins is due to their fungicidal capacity as opposed to fluconazole’s fungistatic effect. The AUCₜot/MIC to attain a 1 log₁₀ CFU/ml kill at 24 h in 100% plasma in our study is of similar magnitude as previously shown by Andes et al in a neutropenic mouse model, in which it was calculated from the free unbound concentration and the AUCfree/MIC. In the clinical study previously published by our...
TABLE 2 Change in pharmacodynamics as represented by 1 log₁₀ CFU/ml kill 24 h at different plasma protein levels in the three caspofungin susceptible Candida glabrata strains: ARU455, ARU459 and ARU767

| Plasma protein levels | ARU455 MIC 0.06 mg/L | ARU459 MIC 0.06 mg/L | ARU767 MIC 0.12 mg/L | All three strains mean ± SD |
|-----------------------|----------------------|----------------------|----------------------|-----------------------------|
|                       | 100% | 50% | 25% | 100% | 50% | 25% | 100% | 50% | 25% | 100% | 50% | 25% |
| Total caspofungin concentration achieving 1 log₁₀ CFU/ml reduction at 24 h, mg/L | 0.67 | 0.54 | 0.21 | 0.75 | 0.44 | 0.09 | 1.25 | 0.66 | 0.20 | 0.89 | 0.55 | 0.11 | 0.17 ± 0.07 |
| 1 log₁₀ CFU/ml kill 24-h AUC₂₀₄₃, mg x h/L | 16.2 | 13.0 | 5.1 | 18.0 | 10.5 | 2.1 | 29.9 | 15.9 | 4.8 | 214 ± 7.4 | 13.1 ± 2.7 | 4.0 ± 1.7 |
| 1 log₁₀ CFU/ml kill 24-h AUC₂₀₄₃/MIC | 270 | 217 | 85 | 300 | 175 | 35 | 273 | 175 | 40 | 273 ± 25 | 175 ± 42 | 54 ± 27 |
| Reduction of AUC₂₀₄₃ from 100% plasma | - | 20% | 68% | - | 42% | 88% | - | 47% | 84% | - | 36 ± 12% | 80 ± 9% |
| Increase in fungal killing | - | 24% | 216% | - | 71% | 746% | - | 88% | 521% | - | 61 ± 27% | 494 ± 217% |

*From the starting inoculum.

The abundance of charged amino acid residues on the albumin molecule makes it an effective plasma buffer and the presence of the protein-bound fraction to the fungal target enzyme, as hypothesized for posaconazole. 20 The abundance of charged amino acid residues on the albumin molecule makes it an effective plasma buffer and the presence of the protein-bound fraction to the fungal target enzyme, as hypothesized for posaconazole. 20 The abundance of charged amino acid residues on the albumin molecule makes it an effective plasma buffer and the presence of the protein-bound fraction to the fungal target enzyme, as hypothesized for posaconazole. 20 The abundance of charged amino acid residues on the albumin molecule makes it an effective plasma buffer and the presence of the protein-bound fraction to the fungal target enzyme, as hypothesized for posaconazole. 20 The abundance of charged amino acid residues on the albumin molecule makes it an effective plasma buffer and the presence of the protein-bound fraction to the fungal target enzyme, as hypothesized for posaconazole. 20
absence of hydrogen ions could potentially affect the protein binding of caspofungin. However, despite using near-net static caspofungin concentrations of 0.5 and 1 mg/L, the effects of which are vulnerable to protein binding changes, differences in pH did not result in any substantial differences in fungal killing in any of the strains. Our results imply that acid-base disturbances, often identified in critically ill patients, will not significantly affect PD and the relationship between free and unbound caspofungin.

Our study has some limitations that may have influenced the results. One limitation is that free and unbound caspofungin was not analysed but the assumption that the free fraction is increased when plasma proteins levels are reduced seems reasonable and clinically, the effect on fungal growth is a parameter of substantial interest. In this in vitro model, the reduction of plasma proteins is achieved by dilution. A limitation when extrapolating our results to the in vivo situation is that in the critically ill, the magnitude of reduction of the different plasma proteins is not the same and albumin may be more reduced than other plasma proteins. Conversely, balanced solutions, such as Ringer’s Acetate used in the present study, are often applied for fluid resuscitation in septic patients and often in large volumes. Moreover, it is not in detail known to which proteins caspofungin binds. On this point, a strength with our model is that all plasma proteins are reduced to a similar degree by the dilution. Finally, our findings offer one possible explanation to an effect in these medically complex patients not reaching target concentrations. Other theoretically potential explanations with some in vitro evidence might be interactions with the host defence, rapid flux from plasma proteins to the fungal enzyme, or in the case of hyphae-producing species, albumin-induced delivery to germinating hyphae. Furthermore, a human target has not been established but is derived from studies in mice in which the deviation was substantial making possible lower target than previously stated.

In conclusion, reduced plasma protein levels in vitro increase the antifungal activity of caspofungin and lower the pharmacodynamic target AUC\text{tot}/MIC, most likely by increasing the free concentration. Thus, low plasma protein levels may constitute one explanation to the successful response in clinical trials on patients with candidemia that exceeds what can be expected from generally accepted target attainment. If TDM is performed, the present results suggest that plasma protein levels should be considered when assessing the expected PD activity based on the total caspofungin concentration. Ultimately, free drug concentrations should be measured when possible.

ACKNOWLEDGEMENTS
The authors would like to thank Karin Vickberg for excellent laboratory assistance.

CONFLICT OF INTEREST
JS has received lecture fees from Gilead and Unimedica Pharma and reimbursement for expert testimonies from Unimedica Pharma. MF has received lecture fees from Pfizer, Gilead and Unimedica Pharma. All other authors: none to declare.

AUTHOR CONTRIBUTIONS
Siri Kurland: Conceptualization (equal); Data curation (equal); Formal analysis (lead); Investigation (equal); Methodology (lead); Project administration (lead); Writing-original draft (equal); Writing-review & editing (equal). Elisabeth Löwdin: Conceptualization (equal); Methodology (equal); Writing-review & editing (equal). Mia Furebring: Conceptualization (equal);
Methodology (equal); Project administration (equal); Writing-review & editing (equal). Ayda Shams: Data curation (equal); Investigation (equal); Methodology (lead); Writing-review & editing (equal). Erja Chryssanthou: Formal analysis (equal); Methodology (equal); Writing-review & editing (equal). Pernilla Lagerbäck: Project administration (equal); Resources (equal); Writing-review & editing (equal). Thomas Tängdén: Funding acquisition (supporting); Resources (equal); Writing-review & editing (equal). Olof Breuer: Formal analysis (equal); Writing-review & editing (equal). Jan Sjölin: Conceptualization (equal); Formal analysis (equal); Funding acquisition (lead); Supervision (equal); Writing-original draft (equal); Writing-review & editing (equal).

ORCID
Siri Kurland https://orcid.org/0000-0002-0034-0609
Erja Chryssanthou https://orcid.org/0000-0003-0627-112X

REFERENCES
1. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323-2329.
2. Hajdu R, Thompson R, Sundelof JG, et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob Agents Chemother. 1997;41:2339-2344.
3. Stone JA, Xu X, Winchell GA, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother. 2004;48:815-823.
4. Andes D, Diekema DJ, Pfaffer MA, et al. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother. 2010;54:2497-2506.
5. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1-e50.
6. Martin-Loeches I, Antonelli M, Cuenca-Estrella M, et al. ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med. 2019;45:789-805.
7. Caironi P, Tognoni G, Masson S, et al. Human plasma protein levels alter the in vitro antifungal protein-bound serum concentration. Antimicrob Agents Chemother. 2004;48:3294-3299.
8. Muilwijk EW, Schouten JA, van Leeuwen HJ, et al. Pharmacokinetics of caspofungin in ICU patients. J Antimicrob Chemother. 2010;54:3964-3966.
9. van Wanrooy MJP, Rodgers MGG, Uges DRA, et al. Low but sufficient anidulafungin exposure in critically ill patients. Antimicrob Agents Chemother. 2014;58:304-308.
10. Rabbani G, Ahn SN. Structure, enzymatic activities, glycation and therapeutic potential of human serum albumin: a natural cargo. Int J Biol Macromol. 2019;123:979-990.
11. Rabbani G, Ahn SN. Structure, enzymatic activities, glycation and therapeutic potential of human serum albumin: a natural cargo. Int J Biol Macromol. 2019;123:979-990.
12. Bader JC, Bhavnani SM, Andes DR, et al. We can do better: a fresh look at echinocandin dosing. J Antimicrob Chemother. 2018;73:831.
13. Zeitlinger MA, Derendorf H, Mouton JW, et al. Protein binding: do we ever learn? Antimicrob Agents Chemother. 2011;55:3067-3074.
14. Sime FB, Byrne CJ, Parker S, et al. Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients. Crit Care. 2019;23:205.
15. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020-2029.
16. Pappas PG, Rotstein CMF, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883-893.
17. Reboli AC, Shorr AF, Rotstein C, et al. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis. 2011;11:261.
18. Kontoyiannis DP, Bassetti M, Nucci M, et al. Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: analysis of pooled data from six prospective clinical studies. Mycoses. 2017;60:663-667.
19. Pfaffer MA, Messer SA, Woosley LN, et al. Echinocandin and triazol antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013;51:2571-2581.
20. Lignell A, Löwdin E, Cars O, et al. Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration. Antimicrob Agents Chemother. 2011;55:3099-3104.
21. Nguyen TH, Hoppe-Tichy T, Geiss HK, et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother. 2007;60:100-106.
22. van Wanrooy MJP, Rodgers MGG, Uges DRA, et al. Low but sufficient anidulafungin exposure in critically ill patients. Antimicrob Agents Chemother. 2014;58:304-308.
23. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-317.
24. Andes DR, Saadar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54:1110-1122.
25. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304-377.
26. Ries F, Afflen A, Aranda Lopez D, et al. Antifungal drugs influence neutrophil effector functions. Antimicrob Agents Chemother. 2019;63:e02409-18.
27. Tullio V, Mandras N, Scals D, et al. Synergy of caspofungin with human polymorphonuclear granulocytes for killing Candida albicans. Antimicrob Agents Chemother. 2010;54:3964-3966.
28. Ioannou P, Andrianaki A, Akoumianaki T, et al. Albumin enhances caspofungin activity against aspergillus species by facilitating drug delivery to germinating hyphae. Antimicrob Agents Chemother. 2015;60:1226-1233.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Kurland S, Löwdin E, Furebring M, et al. Human plasma protein levels alter the in vitro antifungal activity of caspofungin: An explanation to the effect in critically ill? Mycoses. 2022;65:79–87. https://doi.org/10.1111/myc.13386